Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linerixibat - GSK

Next Previous
X
Search
Drug Profile

Linerixibat - GSK

Alternative Names: GSK 2330672; GSK 672

Latest Information Update: 28 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Antihyperglycaemics; Antipruritics; Benzene derivatives; Carboxylic acids; Ethers; Small molecules; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pruritus
  • Phase II Primary biliary cirrhosis; Type 2 diabetes mellitus
  • No development reported Cholestasis

Most Recent Events

  • 10 Nov 2023 Pharmacodynamics data from the phase II GLIMMER trial in Pruritus presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 06 Dec 2022 GlaxoSmithKline completes a phase I trial for Pruritus (In volunteers) in USA (NCT05393076)
  • 06 Dec 2022 Phase-III clinical trials in Pruritus (In adults, In the elderly) in Mexico, Israel, Greece, Greece, France, Czech Republic, China, Canada, Bulgaria, Brazil (PO) (NCT04950127) (EudraCT2021-000007-21)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top